GB929406A - A process for the production of encapsulated material - Google Patents
A process for the production of encapsulated materialInfo
- Publication number
- GB929406A GB929406A GB3916259A GB3916259A GB929406A GB 929406 A GB929406 A GB 929406A GB 3916259 A GB3916259 A GB 3916259A GB 3916259 A GB3916259 A GB 3916259A GB 929406 A GB929406 A GB 929406A
- Authority
- GB
- United Kingdom
- Prior art keywords
- gelatine
- treatment
- preparations
- membranes
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000463 material Substances 0.000 title abstract 2
- 229920000159 gelatin Polymers 0.000 abstract 6
- 235000019322 gelatine Nutrition 0.000 abstract 6
- 239000001828 Gelatine Substances 0.000 abstract 5
- 239000000084 colloidal system Substances 0.000 abstract 4
- 239000000839 emulsion Substances 0.000 abstract 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 abstract 4
- 238000002360 preparation method Methods 0.000 abstract 4
- 229940074391 gallic acid Drugs 0.000 abstract 3
- 239000012528 membrane Substances 0.000 abstract 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 abstract 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 abstract 2
- 239000001263 FEMA 3042 Substances 0.000 abstract 2
- 102000008946 Fibrinogen Human genes 0.000 abstract 2
- 108010049003 Fibrinogen Proteins 0.000 abstract 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 abstract 2
- 108010039918 Polylysine Proteins 0.000 abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 2
- 238000005354 coacervation Methods 0.000 abstract 2
- COVFEVWNJUOYRL-UHFFFAOYSA-N digallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 COVFEVWNJUOYRL-UHFFFAOYSA-N 0.000 abstract 2
- 229940012952 fibrinogen Drugs 0.000 abstract 2
- 235000004515 gallic acid Nutrition 0.000 abstract 2
- 239000003921 oil Substances 0.000 abstract 2
- 229920000656 polylysine Polymers 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 235000015523 tannic acid Nutrition 0.000 abstract 2
- 229920002258 tannic acid Polymers 0.000 abstract 2
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 abstract 2
- 229940033123 tannic acid Drugs 0.000 abstract 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 abstract 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 abstract 1
- 229930182837 (R)-adrenaline Natural products 0.000 abstract 1
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 abstract 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 abstract 1
- PYSRRFNXTXNWCD-UHFFFAOYSA-N 3-(2-phenylethenyl)furan-2,5-dione Chemical compound O=C1OC(=O)C(C=CC=2C=CC=CC=2)=C1 PYSRRFNXTXNWCD-UHFFFAOYSA-N 0.000 abstract 1
- 229920002707 Digallic acid Polymers 0.000 abstract 1
- 108010010803 Gelatin Proteins 0.000 abstract 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 abstract 1
- QYZBCWXZSYTIOY-UHFFFAOYSA-N Mercuric oxide Chemical compound [O-2].[Hg+2] QYZBCWXZSYTIOY-UHFFFAOYSA-N 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 abstract 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 abstract 1
- 229920000147 Styrene maleic anhydride Polymers 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 239000003899 bactericide agent Substances 0.000 abstract 1
- 238000001816 cooling Methods 0.000 abstract 1
- 239000002285 corn oil Substances 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960005139 epinephrine Drugs 0.000 abstract 1
- 239000003337 fertilizer Substances 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 239000002778 food additive Substances 0.000 abstract 1
- 235000013373 food additive Nutrition 0.000 abstract 1
- 239000008273 gelatin Substances 0.000 abstract 1
- 235000011852 gelatine desserts Nutrition 0.000 abstract 1
- 229940075507 glyceryl monostearate Drugs 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 229960003210 hyoscyamine Drugs 0.000 abstract 1
- 229930005342 hyoscyamine Natural products 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 229940101209 mercuric oxide Drugs 0.000 abstract 1
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(II) oxide Inorganic materials [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 abstract 1
- 239000003094 microcapsule Substances 0.000 abstract 1
- 239000002480 mineral oil Substances 0.000 abstract 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 abstract 1
- 239000000575 pesticide Substances 0.000 abstract 1
- 229940096826 phenylmercuric acetate Drugs 0.000 abstract 1
- 230000008635 plant growth Effects 0.000 abstract 1
- 229920000768 polyamine Polymers 0.000 abstract 1
- 108010055896 polyornithine Proteins 0.000 abstract 1
- 229920002714 polyornithine Polymers 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 229960004839 potassium iodide Drugs 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 abstract 1
- 229960003147 reserpine Drugs 0.000 abstract 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 abstract 1
- 229920002545 silicone oil Polymers 0.000 abstract 1
- 150000003378 silver Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/26—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests in coated particulate form
- A01N25/28—Microcapsules or nanocapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/10—Complex coacervation, i.e. interaction of oppositely charged particles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Agronomy & Crop Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Colloid Chemistry (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
The walls of microcapsules comprised of at least one gelable hydrophilic colloid which contains amino groups and peptide linkages and produced by a coacervation process (see Group VI) are rendered opaque and their impermeability to fluids increased by successive treatment with (a) at least one watersoluble and ionizable ferric salt and, (b) an aqueous solution of one or more of tannic acid, gallic acid and di-gallic acid. Specified colloids of the above type are gelatin, fibrinogen, polylysine and polyrnithine. Specifications 751,600, 911,483, 929,401, 929,402, 929,403, 929,408 and 929,409 are referred to.ALSO:Membranes comprising at least one gelable hydrophilic colloid which contains amino groups and peptide linkages (e.g. proteins and polyamines) and produced by coacervation techniques are treated successively with: (1) at least one water-soluble and ionizable ferric salt and (2) an aqueous solution of one or more of tannic acid, gallic acid and digallic acid. The membranes may encapsulate solids, oils, oil-in-hydrophilic liquid and hydrophilic liquid-in-oil emulsions which may contain "active" ingredients which render the preparations of use as fertilizers, plant growth hormone preparations, bactericides, pesticides, vitamin preparations, pharmaceuticals and food-additives. In particular, the treatment renders the membranes opaque and therefore increases the stability of encapsulated preparations comprising photosensitive materials, e.g. reserpine, hyoscyamine, potassium iodide, silver salts and phenyl mercuric acetate. Specified colloids are gelatine, fibrinogen, polylysine and polyornithine. The coacervate must be gelled (e.g. by cooling) prior to the treatment with the ferric salt and may be present in the "spent" coacervating medium during the first or both steps of the treatment which preferably takes place at a pH of below 7. Specific examples refer to the treatment of: (a) aqueous potassium iodide-in-corn oil emulsion encapsulated in gelatine; (b) an ethanolic dispersion of silverbromide-in-silicone oil emulsion in gelatine; (c) aqueous epinephrine bitartrate-in-mineral oil emulsion in a complex coacervate of gelatine and styrene-maleic anhydride copolymer; (d) glyceryl monostearate coated yellow mercuric oxide in gelatine. Specifications 751,600, 911,483, 929,401, 929,402, 929,403, 929,408 and 929,409 are referred to.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78193058A | 1958-12-22 | 1958-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB929406A true GB929406A (en) | 1963-06-19 |
Family
ID=25124414
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB3916259A Expired GB929406A (en) | 1958-12-22 | 1959-11-18 | A process for the production of encapsulated material |
| GB3916159A Expired GB929405A (en) | 1958-12-22 | 1959-11-18 | Processes for the encapsulation of particles |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB3916159A Expired GB929405A (en) | 1958-12-22 | 1959-11-18 | Processes for the encapsulation of particles |
Country Status (3)
| Country | Link |
|---|---|
| CH (1) | CH396845A (en) |
| DE (1) | DE1141263B (en) |
| GB (2) | GB929406A (en) |
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4808408A (en) * | 1983-05-11 | 1989-02-28 | Bend Research, Inc. | Microcapsules prepared by coacervation |
| WO2001026627A1 (en) * | 1999-10-14 | 2001-04-19 | 1170535 Ontario Inc. | Liposome encapsulated silver salt compositions |
| WO2013123492A2 (en) | 2012-02-17 | 2013-08-22 | Massachusetts Institute Of Technology | Glucose-responsive microgels for closed loop insulin delivery |
| WO2013138346A1 (en) | 2012-03-16 | 2013-09-19 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
| WO2013138343A1 (en) | 2012-03-16 | 2013-09-19 | The Johns Hopkins University | Controlled release formulations for the delivery of hif-1 inhibitors |
| WO2014160404A1 (en) | 2013-03-13 | 2014-10-02 | The Regents Of The University Of California | Improved oral drug devices and drug formulations |
| WO2015106106A1 (en) | 2014-01-10 | 2015-07-16 | Chamber Works, Llc | A personalizing substance for application to the skin or addition to tattoo ink and methods of preparation thereof |
| WO2015138951A1 (en) | 2014-03-14 | 2015-09-17 | Chamber Works, Llc | Articles of jewelry containing a personalizing additive such as dna and methods of making |
| WO2016100392A1 (en) | 2014-12-15 | 2016-06-23 | The Johns Hopkins University | Sunitinib formulations and methods for use thereof in treatment of ocular disorders |
| WO2016118506A1 (en) | 2015-01-20 | 2016-07-28 | The Johns Hopkins University | Compositions for the sustained release of anti-glaucoma agents to control intraocular pressure |
| WO2017035408A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
| WO2017041053A1 (en) | 2015-09-04 | 2017-03-09 | Yale University | Polymeric bile acid nanocompositions targeting the pancreas and colon |
| WO2017143061A1 (en) | 2016-02-16 | 2017-08-24 | Yale University | Compositions and methods for treatment of cystic fibrosis |
| WO2017143042A2 (en) | 2016-02-16 | 2017-08-24 | Yale University | Compositions for enhancing targeted gene editing and methods of use thereof |
| WO2017151879A1 (en) | 2016-03-02 | 2017-09-08 | The Johns Hopkins University | Compositions for sustained release of anti-glaucoma agents to control intraocular pressure |
| US9822364B2 (en) | 2008-03-11 | 2017-11-21 | Yale University | Compositions and methods for controlled delivery of inhibitory ribonucleic acids |
| WO2018005552A1 (en) | 2016-06-27 | 2018-01-04 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
| WO2018053010A1 (en) | 2016-09-13 | 2018-03-22 | North Carolina State University | Platelet compositions and methods for the delivery of therapeutic agents |
| WO2018187493A1 (en) | 2017-04-04 | 2018-10-11 | Yale University | Compositions and methods for in utero delivery |
| US10441548B2 (en) | 2015-11-12 | 2019-10-15 | Graybug Vision, Inc. | Aggregating microparticles for medical therapy |
| WO2020028907A1 (en) | 2018-08-03 | 2020-02-06 | Brown University | Compositions and methods for improving the bioavailability of glp1 and analogues thereof |
| WO2020033951A1 (en) | 2018-08-10 | 2020-02-13 | Yale University | Compositions and methods for embryonic gene editing in vitro |
| US10722468B2 (en) | 2014-08-14 | 2020-07-28 | Brown University | Compositions for stabilizing and delivering proteins |
| US11160870B2 (en) | 2017-05-10 | 2021-11-02 | Graybug Vision, Inc. | Extended release microparticles and suspensions thereof for medical therapy |
| WO2021258042A1 (en) | 2020-06-19 | 2021-12-23 | Yale University | Polymeric bile acid ester nanoparticles comprising an immunomodulator agent to induce antigen-specific tolerance |
| WO2022115474A1 (en) | 2020-11-27 | 2022-06-02 | General Nanotherapeutics Llc | Methods and composition for treatment of immune-mediated diseases |
| EP4053117A1 (en) | 2015-08-26 | 2022-09-07 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3965033A (en) * | 1970-07-27 | 1976-06-22 | Fuji Photo Film Co., Ltd. | Process for the production of oil-containing microcapsules |
| CA1044134A (en) * | 1975-04-09 | 1978-12-12 | Minnesota Mining And Manufacturing Company | Microcapsule insecticide composition |
| FR2464093A1 (en) * | 1979-08-30 | 1981-03-06 | Roussel Uclaf | PROCESS FOR THE PREPARATION OF SUSPENSIONS OR STABLE POWDERS OF STABLE MICROCAPSULES WITH VARIABLE POROSITY AND THE PRODUCTS OBTAINED THEREBY |
| DE3016170A1 (en) * | 1980-04-26 | 1981-10-29 | Bayer Ag, 5090 Leverkusen | MICROCAPSULES WITH A DEFINED OPENING TEMPERATURE, METHOD FOR THE PRODUCTION AND USE THEREOF |
| FR2857592B1 (en) * | 2003-07-18 | 2006-02-24 | Sod Conseils Rech Applic | NEW PROCESS FOR THE PREPARATION OF MICROPARTICLES |
| WO2005105057A1 (en) | 2004-04-23 | 2005-11-10 | Amgen Inc. | Sustained release formulations |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2800457A (en) * | 1953-06-30 | 1957-07-23 | Ncr Co | Oil-containing microscopic capsules and method of making them |
-
1959
- 1959-11-18 GB GB3916259A patent/GB929406A/en not_active Expired
- 1959-11-18 GB GB3916159A patent/GB929405A/en not_active Expired
- 1959-12-16 DE DEU6742A patent/DE1141263B/en active Pending
- 1959-12-19 CH CH8206059A patent/CH396845A/en unknown
Cited By (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4808408A (en) * | 1983-05-11 | 1989-02-28 | Bend Research, Inc. | Microcapsules prepared by coacervation |
| WO2001026627A1 (en) * | 1999-10-14 | 2001-04-19 | 1170535 Ontario Inc. | Liposome encapsulated silver salt compositions |
| US9822364B2 (en) | 2008-03-11 | 2017-11-21 | Yale University | Compositions and methods for controlled delivery of inhibitory ribonucleic acids |
| WO2013123492A2 (en) | 2012-02-17 | 2013-08-22 | Massachusetts Institute Of Technology | Glucose-responsive microgels for closed loop insulin delivery |
| WO2013138346A1 (en) | 2012-03-16 | 2013-09-19 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
| WO2013138343A1 (en) | 2012-03-16 | 2013-09-19 | The Johns Hopkins University | Controlled release formulations for the delivery of hif-1 inhibitors |
| WO2014160404A1 (en) | 2013-03-13 | 2014-10-02 | The Regents Of The University Of California | Improved oral drug devices and drug formulations |
| WO2015106106A1 (en) | 2014-01-10 | 2015-07-16 | Chamber Works, Llc | A personalizing substance for application to the skin or addition to tattoo ink and methods of preparation thereof |
| US9539187B2 (en) | 2014-01-10 | 2017-01-10 | Chamber Works, Llc | Personalizing substance for application to the skin or addition to tattoo ink and methods of preparation thereof |
| US9539186B2 (en) | 2014-01-10 | 2017-01-10 | Chamber Works, Llc | Personalizing substance for application to the skin or addition to tattoo ink and methods of preparation thereof |
| US9610229B2 (en) | 2014-01-10 | 2017-04-04 | Chamber Works, Llc | Personalizing substance for application to the skin or addition to tattoo ink and methods of preparation thereof |
| WO2015138951A1 (en) | 2014-03-14 | 2015-09-17 | Chamber Works, Llc | Articles of jewelry containing a personalizing additive such as dna and methods of making |
| US11504329B2 (en) | 2014-08-14 | 2022-11-22 | Brown University | Compositions for stabilizing and delivering proteins |
| US10722468B2 (en) | 2014-08-14 | 2020-07-28 | Brown University | Compositions for stabilizing and delivering proteins |
| WO2016100380A1 (en) | 2014-12-15 | 2016-06-23 | The Johns Hopkins University | Sunitinib formulations and methods for use thereof in treatment of glaucoma |
| US10525034B2 (en) | 2014-12-15 | 2020-01-07 | The Johns Hopkins University | Sunitinib formulations and methods for use thereof in treatment of glaucoma |
| WO2016100392A1 (en) | 2014-12-15 | 2016-06-23 | The Johns Hopkins University | Sunitinib formulations and methods for use thereof in treatment of ocular disorders |
| US11013719B2 (en) | 2014-12-15 | 2021-05-25 | The Johns Hopkins University | Sunitinib formulations and methods for use thereof in treatment of glaucoma |
| WO2016118506A1 (en) | 2015-01-20 | 2016-07-28 | The Johns Hopkins University | Compositions for the sustained release of anti-glaucoma agents to control intraocular pressure |
| WO2017035408A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
| EP4053117A1 (en) | 2015-08-26 | 2022-09-07 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders |
| WO2017041053A1 (en) | 2015-09-04 | 2017-03-09 | Yale University | Polymeric bile acid nanocompositions targeting the pancreas and colon |
| US10441548B2 (en) | 2015-11-12 | 2019-10-15 | Graybug Vision, Inc. | Aggregating microparticles for medical therapy |
| US11564890B2 (en) | 2015-11-12 | 2023-01-31 | Graybug Vision, Inc. | Aggregating microparticles for medical therapy |
| US11331276B2 (en) | 2015-11-12 | 2022-05-17 | Graybug Vision, Inc. | Aggregating microparticles for medical therapy |
| WO2017143042A2 (en) | 2016-02-16 | 2017-08-24 | Yale University | Compositions for enhancing targeted gene editing and methods of use thereof |
| WO2017143061A1 (en) | 2016-02-16 | 2017-08-24 | Yale University | Compositions and methods for treatment of cystic fibrosis |
| WO2017151879A1 (en) | 2016-03-02 | 2017-09-08 | The Johns Hopkins University | Compositions for sustained release of anti-glaucoma agents to control intraocular pressure |
| WO2018005552A1 (en) | 2016-06-27 | 2018-01-04 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
| WO2018053010A1 (en) | 2016-09-13 | 2018-03-22 | North Carolina State University | Platelet compositions and methods for the delivery of therapeutic agents |
| WO2018187493A1 (en) | 2017-04-04 | 2018-10-11 | Yale University | Compositions and methods for in utero delivery |
| US11160870B2 (en) | 2017-05-10 | 2021-11-02 | Graybug Vision, Inc. | Extended release microparticles and suspensions thereof for medical therapy |
| WO2020028907A1 (en) | 2018-08-03 | 2020-02-06 | Brown University | Compositions and methods for improving the bioavailability of glp1 and analogues thereof |
| WO2020033951A1 (en) | 2018-08-10 | 2020-02-13 | Yale University | Compositions and methods for embryonic gene editing in vitro |
| WO2021258042A1 (en) | 2020-06-19 | 2021-12-23 | Yale University | Polymeric bile acid ester nanoparticles comprising an immunomodulator agent to induce antigen-specific tolerance |
| WO2022115474A1 (en) | 2020-11-27 | 2022-06-02 | General Nanotherapeutics Llc | Methods and composition for treatment of immune-mediated diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| GB929405A (en) | 1963-06-19 |
| CH396845A (en) | 1965-08-15 |
| DE1141263B (en) | 1962-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB929406A (en) | A process for the production of encapsulated material | |
| GB930422A (en) | Process of the encapsulation of particulate material | |
| DE69430491D1 (en) | METHOD FOR ENCLOSURE NSAIDS | |
| GB1298194A (en) | Improved method for encapsulating aqueous or hydrophilic material, the capsules obtained therewith and their application | |
| Merkle et al. | Preparation and in vitro evaluation of cellulose acetate phthalate coacervate microcapsules | |
| ES416960A1 (en) | Process for hardening microcapsules containing hydrophobic oil droplets | |
| JPS56161833A (en) | Preparation of microcapsule in liquid vehicle | |
| NZ208579A (en) | Encapsulating organic compounds whose solubility varies according to ph | |
| US3639259A (en) | Enzymatic treatment of gelled proteinaceous film material | |
| Adams et al. | Pectinase in the saliva of Myzus persicae (Sulz.)(Homoptera: Aphididae) | |
| EP0453316B1 (en) | Process for preparation of microcapsules | |
| ES341431A1 (en) | Wall-sealing treatment for minute capsules and minute capsules having walls of sealed polymeric material | |
| KR900700082A (en) | Gelcore | |
| ES400342A1 (en) | Process for preparing microscopic capsules containing hydrophobic oil droplets therein | |
| GB929404A (en) | Processes for the encapsulation of particulate material | |
| DE69410605T2 (en) | METHOD FOR ENCAPPING SUBSTANCES IN BIOCAPSULES | |
| ES427055A1 (en) | Oil-containing microcapsules and a process for their production | |
| GB1139964A (en) | A method of preparing minute capsules having gelatin-containing walls | |
| GB929407A (en) | Dicarbonyl treatment | |
| GB1234805A (en) | A process for the encapsulating of hydrophobic materials | |
| JPS55141405A (en) | Production of microcapsule containing placental extract for cosmetics and cosmetic containing the same | |
| GB1436714A (en) | Medicinal process | |
| GB931532A (en) | Injectable preparations comprising encapsulated medicaments and processes for making them | |
| US1783334A (en) | Colloidal silver iodide compound and method of preparing same | |
| Uraguchi | Rhythmic banding in protoplasm |